Fuyuan Pharmaceuticals (601089.SH): Type 1 innovative drug FY101 injection is still in Phase I clinical trial stage.

Zhtng Cijng APP news, Fyun Yyo (601089.SH) released a stock price abnormal announcement stating that the company has noted a high level of attention in the market towards its innovative pharmaceutical business in recent times. On April 9, 2025, the company disclosed the "Announcement of Beijing Fuyuan Pharmaceutical Co., Ltd. on Obtaining the Notice of Approval for Clinical Trials of Drugs". The company's first class innovative drug FY101 injection received the Notice of Approval for Clinical Trials of Drugs. As of the date of the announcement, the project is still in the Phase I clinical trial stage, and there is still significant uncertainty on whether the trial will be successful. In addition to the above information, the company has not found any other media reports or market rumors that may have a significant impact on the company's stock trading price, and it does not involve other market hot topics.